Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo Aims at Top Share in CV Field: Mr Shoda
October 20, 2008
- Industry Split over Online Sale of OTC Drugs
October 20, 2008
- Shionogi Completes TOB on Sciele
October 20, 2008
- % of Prescriptions Permitting Generic Substitution Decreasing: Survey
October 20, 2008
- AnGes MG Negotiates Rights to New-Type Influenza DNA Vaccine with Vical
October 20, 2008
- 67% of Pharmacies Have Demanded Premium for Generics Dispensing System
October 20, 2008
- Eli Lilly to Acquire ImClone for US$6.5 Billion
October 20, 2008
- Final Draft of Peptic Ulcer Guidelines Approved
October 20, 2008
- Novartis Enhances Sales/Marketing by Therapeutic Category
October 20, 2008
- Routine Use of PCV7 Is Cost-Effective: Wyeth
October 20, 2008
- BUSINESS NEWS IN BRIEF
October 20, 2008
- Japan's First ACS Patient Registry Study PACIFIC Underway
October 20, 2008
- Thalidomide to Be Approved for Multiple Myeloma
October 20, 2008
- Astellas Completes New Buildings in Its Tsukuba Research Center
October 20, 2008
- Industry Should Stress Contribution to Healthcare: Mr Kinoshita
October 20, 2008
- Kissei's Silodosin Approved in US
October 20, 2008
- To Promote Use of Generics or Cut Prices of Original Drugs?
October 20, 2008
- Otsuka Extends Joint Research Program with Galenea for 1 Year
October 20, 2008
- Korosho to Survey Code Labeling of Drugs
October 13, 2008
- 97% of Hospitals Protect ED Patient Privacy: Lilly Survey
October 13, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…